BK Virus Testing Market: By Sample Extract (Blood and Urine), By End User (Hospitals, Diagnostic Centers, and Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

BK Virus Testing Market size was valued at USD 273.5 million in 2022, growing at a 13.5% CAGR from 2024 to 2030. The test is ordered for the detection and quantification of the BK virus in the blood or urine. Determination of BK viral load helps diagnose and treat BK virus-related morbidity. BK virus is rarely known to cause a disease but is typically associated with patients who have had a kidney transplant. However, many people who are infected with the BK virus do not show any symptoms. And in case the symptoms do appear, they are mild, such as a respiratory infection or fever. 

The quantification range of this assay is 200 to 100,000,000 IU/mL (2.30 log to 8.00 log IU/mL), with a limit of detection (95% detection rate) at 12 IU/ml. An "Undetected" test result indicates the absence of BK virus (BKV) DNA in the urine. For instance, the increase in the prevalence of the BK virus among adults raises the diagnosis which drives the market. A regular unhealthy lifestyle damages the kidney and lungs which reflect the increase in transplantation numbers across the world showing the generation of BK virus which leads increase in the testing of the virus. The high cost of tests is the major factor that hinders the growth of the BK virus test market. Geographically, North America held the major market share in 2022 and is expected to dominate the BKV testing market in the forecasted years.

BK Virus Testing Market Key Developments:

In February 2021, Roche announced the U.S. Food and Drug Administration (FDA) 510K clearance of stabilized urine samples to be used with the cobas® BKV Test on the cobas® 6800/8800 Systems.

BK Virus Testing Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
BK Virus Testing Market Dynamics

The increasing prevalence of hepatic diseases and renal diseases across the world is the major market driver in the BKV Testing Market during the forecast period. BK virus also known as polyomavirus is generated in adults mainly after kidney and liver transplants, rise in testing due to it becoming a major disease in the modern era, detection market covers the market. Hence, this will drive the global market growth at a significant rate.

Key Features of the Reports

  • The bk virus testing market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

BK Virus Testing Market Segmentation

By Sample Extract
  • Blood
  • Urine
By End User
  • Hospitals
  • Diagnostic Centres
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The bk virus testing market size was valued at USD 273.5 million in 2022, growing at a 13.5% CAGR from 2024 to 2030

The leading players in the bk virus testing market are Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Diamedix, DiaSorin, Eiken Chemical, and Elitech Group

Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.

  • Abbott
  • Affymetrix
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • Elitech Group

Adjacent Markets